Birchview Capital’s United Therapeutics UTHR Stock Holding History

Birchview Capital’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.44M	Buy	4,506 +6	+0.1%	+$3.38K	1.14%	23
2026 Q1	$2.67M	Buy	4,500 +1,500	+50%	+$747K	1.52%	18
2025 Q4	$1.46M	Hold	3,000	–	–	0.86%	31
2025 Q3	$1.26M	Sell	3,000 -1,250	-29%	-$420K	0.95%	27
2025 Q2	$1.22M	Sell	4,250 -3,250	-43%	-$971K	1.21%	24
2025 Q1	$2.31M	Sell	7,500 -2,500	-25%	-$857K	2.01%	13
2024 Q4	$3.53M	Hold	10,000	–	–	2.87%	8
2024 Q3	$3.58M	Hold	10,000	–	–	3.1%	5
2024 Q2	$3.19M	Sell	10,000 -1,000	-9%	-$265K	2.94%	9
2024 Q1	$2.53M	Hold	11,000	–	–	2.06%	12
2023 Q4	$2.42M	Hold	11,000	–	–	1.89%	11
2023 Q3	$2.48M	Sell	11,000 -4,000	-27%	-$921K	2.11%	9
2023 Q2	$3.31M	Hold	15,000	–	–	2.48%	9
2023 Q1	$3.36M	Hold	15,000	–	–	2.63%	8
2022 Q4	$4.17M	Hold	15,000	–	–	2.95%	8
2022 Q3	$3.14M	Hold	15,000	–	–	2.21%	9
2022 Q2	$3.54M	Sell	15,000 -3,000	-17%	-$610K	2.57%	7
2022 Q1	$3.23M	Hold	18,000	–	–	2.32%	9
2021 Q4	$3.89M	Hold	18,000	–	–	2.51%	9
2021 Q3	$3.32M	Hold	18,000	–	–	2.26%	9
2021 Q2	$3.23M	Hold	18,000	–	–	1.93%	10
2021 Q1	$3.01M	Hold	18,000	–	–	1.79%	10
2020 Q4	$2.73M	Hold	18,000	–	–	1.57%	13
2020 Q3	$1.82M	Hold	18,000	–	–	1.21%	16
2020 Q2	$2.18M	Hold	18,000	–	–	1.32%	12
2020 Q1	$1.71M	Buy	18,000 +13,000	+260%	+$1.24M	1.51%	10
2019 Q4	$440K	Buy	+5,000	New	+$440K	0.32%	36

Other funds holding UTHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Norges Bank Oslo, Norway $1T AUM

Birchview Capital's UTHR Position: Q2 2026 in Review

Birchview Capital increased its United Therapeutics (UTHR) stake by 0.13% in Q2 2026, buying an estimated $3.38K and bringing the position to 4,506 shares worth $2.44M. The position accounts for 1.14% of the portfolio, ranked #23.

Birchview Capital first reported a position in UTHR in Q4 2019 and has held it in 27 quarters since. The position peaked at $4.17M in Q4 2022. 880 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

Birchview Capital held 4,506 shares of United Therapeutics worth $2.44M as of Q2 2026.
Birchview Capital bought 6 United Therapeutics shares in Q2 2026, an estimated $3.38K.
United Therapeutics made up 1.14% of Birchview Capital's portfolio in Q2 2026, its #23 holding.
Birchview Capital first reported a position in United Therapeutics in Q4 2019 and has held it in 27 quarters since.
Birchview Capital's United Therapeutics position peaked at $4.17M in Q4 2022.
880 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Birchview Capital's 13F filing for Q2 2026, filed 14 Aug 2026.